Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Evolus exceeds revenue targets, poised for growth with Evolysse launch

Evolus had a remarkable year in 2024, achieving profitability, expanding its market reach, and securing key regulatory approvals. The upcoming launch of Evolysse and strong revenue guidance indicate a promising future for the company, although challenges in sustaining growth and managing expenses persist.

Evolus reports robust Q1 performance, eyes growth opportunities ahead

Evolus is on a positive trajectory with strong revenue growth, successful product launches, and a focus on customer engagement. The company remains confident in achieving profitability and expects continued growth driven by its neurotoxin business and new injectable hyaluronic acid gels.

Evolus Q2 earnings below expectations, eyes profitability in 2026

Evolus faced challenges in Q2 but is optimistic about market share gains and revenue growth. The company is strategically adjusting its operations to achieve profitability in 2026 while focusing on expanding internationally and capitalizing on positive momentum.

Evolus (EOLS) posts strong Q4 earnings, eyes market expansion

Evolus (EOLS) delivered a robust performance in Q4 2025, driven by strong international revenue growth, innovative product launches, and strategic marketing initiatives. While facing challenges in competitive dynamics and operational efficiency, the company remains optimistic about its position, portfolio expansion, and profitability goals. With a clear focus on beauty strategies, customer engagement, and financial discipline, Evolus is poised to capitalize on opportunities for sustained growth and market leadership.

Evolus reports robust Q1 results, eyes European expansion for growth

Evolus' Q1 performance showcases strong financials, market share retention, and revenue growth. With a focus on innovation and market expansion, the company is poised for continued success in the beauty aesthetics industry.